Results 121 to 130 of about 20,735 (212)

Efficacy of Immunostimulatory Adjuvants and Nano‐Adjuvants in Current SARS‐CoV‐2 Vaccines: A Comprehensive Review

Health Science Reports, Volume 8, Issue 11, November 2025.
ABSTRACT Background and Aims SARS‐CoV‐2 continues to pose global challenges, and current vaccines face limitations (variant escape, waning immunity). This review evaluates immunostimulatory adjuvants and nano‐adjuvants to enhance immune responses and optimize SARS‐CoV‐2 vaccine performance.
Peyman Kheirandish Zarandi, Mohammad Reza Zinatizadeh, Mohsen Ghiasi, Mohammad Rezaei Zadeh Rukerd, Hanieh Mirkamali, Ehsan Shokri   +5 more
wiley   +1 more source

Mucosal‐Associated Invariant T Cells: Origins, Biological Functions, Diseases, and Therapeutic Targets

MedComm, Volume 6, Issue 11, November 2025.
Mucosa‐associated invariant T (MAIT) cells are an evolutionarily conserved class of innate‐like T lymphocytes that rely on MR1 molecules to recognize microbial metabolites and play a central role in immune surveillance and inflammatory regulation.
Cheng Zhu, Qian Huai, Yishan Du, Xingyu Li, Fumin Zhang, Yongkang Zhang, Mengwei Wu, Ying Dai, Xiaolei Li, Hanren Dai, Hua Wang   +10 more
wiley   +1 more source

Seropersistence of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine): 6-month follow-up of a randomized, controlled, observer-blind, phase 2/3 immuno-bridging study in Indian adults

Human Vaccines & Immunotherapeutics
AZD1222 (ChAdOx1 nCoV-19) is a replication-deficient adenoviral vectored coronavirus disease-19 (COVID-19) vaccine that is manufactured as SII-ChAdOx1 nCoV-19 by the Serum Institute of India Pvt Ltd following technology transfer from Oxford University ...
Prasad S. Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, B.S. Garg, Nithya J. Gogtay, Muralidhar Tambe, Sanjay Lalwani, Kiranjit Singh, Renuka Munshi, Sushant Meshram, T.S. Selvavinayagam, Krishna Pandey, Devi Madhavi Bhimarasetty, S.R. Ramakrishnan, Chetanraj Bhamare, Abhijeet Dharmadhikari, Chandrashekhar Budhawant, Cyrille J. Bonhomme, Madhuri Thakar, Swarali N. Kurle, Elizabeth J. Kelly, Manish Gautam, Nivedita Gupta, Samiran Panda, Balram Bhargava, Cyrus S. Poonawalla, Umesh Shaligram, Dhananjay Kapse, Bhagwat Gunale   +31 more
doaj   +1 more source

Impact and Effectiveness of COVID‐19 mRNA Vaccination Against COVID‐19 Hospitalisation in Paediatrics: A Cohort Study Using Two Linked Data Sources in Spain

Pharmacoepidemiology and Drug Safety, Volume 34, Issue 11, November 2025.
ABSTRACT Purpose Despite Spain's > 2 million COVID‐19 paediatric cases before 2024, few required hospitalisations (8900). We aimed to estimate the effectiveness of two‐dose COVID‐19 vaccinations against hospitalisation ‘with’ and ‘for’ COVID‐19 in paediatrics.
Belén Castillo‐Cano, Fabio Riefolo, Felipe Villalobos, Mar Martín‐Pérez, Davide Messina, Roel Elbers, Dorieke Brink‐Kwakkel, Carlo Alberto Bissacco, Elena Segundo, Luis Carlos Saiz, Leire Leache, Elisa Barbieri, Tiago Vaz, Rosa Gini, Olaf Klungel, Elisa Martín‐Merino   +15 more
wiley   +1 more source

Should We Advance Our Understanding of Immunoglobulin E in Viral Immunity?

Immunology, Volume 176, Issue 3, Page 312-321, November 2025.
Immunoglobulin E has been extensively studied in allergies and parasitic diseases. Antigen‐specific IgE has been identified as part of the humoral response to viruses. This revision speculates on possible functionalities for IgE, such as neutralisation, cytotoxicity and immunopathology of viral diseases, and provide insights about gaps to fill in ...
Amanda Izeli Portilho, Valéria Oliveira Silva, Luis Fernando de Macedo Brigido, Elizabeth De Gaspari   +3 more
wiley   +1 more source

VITT after ChAdOx1 nCoV-19 Vaccination

New England Journal of Medicine, 2021
Christian, Weber, Philipp, von Hundelshausen, Wolfgang, Siess   +2 more
openaire   +3 more sources

Consolidating Estimates of the Incubation Period for Omicron Subvariants From the Literature and Their Comparison to the Estimate From Taiwan: A Systematic Review and Meta‐Analysis, September 2024

Influenza and Other Respiratory Viruses, Volume 19, Issue 11, November 2025.
ABSTRACT Background The COVID‐19 pandemic was characterized by waves driven by distinct viral variants, including the Omicron variant, which emerged in October 2021. To formulate effective public health strategies and understand disease spread, accurate estimates of the incubation periods of these variants are important.
Andrei R. Akhmetzhanov, Hao‐Yuan Cheng, Gillian Cheng, Jonathan Dushoff   +3 more
wiley   +1 more source

Greater preservation of SARS‐CoV‐2 neutralising antibody responses following the ChAdOx1‐S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients [PDF]

Summary: Whilst SARS‐CoV‐2 mRNA vaccines generate high neutralising antibodies (nAb) in most individuals, haematopoietic stem cell transplant (HSCT) and chimeric antigen receptor T‐cell (CAR‐T) recipients respond poorly.
Angyal, Adrienn, Barnes, Eleanor, Barratt, Natalie, Bowden, Sarah, Collini, Paul J., Colton, Hayley, Cook, Gordon, Dunachie, Susanna J., Goodyear, Carl S., Grouneva, Irina, Hornsby, Hailey, Kearns, Pamela, Kirkham, Amanda, Kronsteiner, Barbara, Lindsey, Benjamin B., McInnes, Iain B., Orchard, Kim, Pope, Ann, Richter, Alex, Selby, Rachael, Siebert, Stefan, Temperton, Nigel, Thomas, David, Willicombe, Michelle   +23 more
core   +2 more sources

Neurovascular Adverse Effects of Sars-Cov-2 Vaccination

Drug Design, Development and Therapy
Leonidas D Panos,1,2 Panagiotis Bargiotas,2 Georgios Hadjigeorgiou,2 Georgios D Panos3,4 1Department of Neurology, Bern University Hospital « Inselspital », Bern, Switzerland; 2Department of Neurology, School of Medicine, University of Cyprus, Nicosia ...
Panos LD, Bargiotas P, Hadjigeorgiou G, Panos GD   +3 more
doaj  

Durability of the Effectiveness of Heterologous COVID-19 Vaccine Regimens in Thailand: Retrospective Cohort Study Using National Registration Data

JMIR Public Health and Surveillance
BackgroundThe durability of heterologous COVID-19 vaccine effectiveness (VE) has been primarily studied in high-income countries, while evaluation of heterologous vaccine policies in low- and middle-income countries remains ...
Ponlagrit Kumwichar, Chittawan Poonsiri, Siobhan Botwright, Natchalaikorn Sirichumroonwit, Bootsakorn Loharjun, Supharerk Thawillarp, Nontawit Cheewaruangroj, Amorn Chokchaisiripakdee, Yot Teerawattananon, Virasakdi Chongsuvivatwong   +9 more
doaj   +1 more source